Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.52+0.18 (+4.15%)
Close on Nov 19, 2026Market cap $504.03MP/E –Yield –
Gyre Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Gyre Therapeutics's pe ratio was 384.0× on Apr 30, 2026, against 195.2× a year earlier. Over the last 3 years it ranged from 5.4× to 453.5×, with a median of 84.3×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 384.0× | +261.2 |
| 2025 | Dec 31, 2025 | 122.8× | +113.4 |
| 2023 | Jul 31, 2023 | 9.3× | −12.2 |
| 2022 | Dec 30, 2022 | 21.5× | −36.1 |
| 2011 | Oct 31, 2011 | 57.6× | – |
See a number that looks wrong?